Ubs Group Ag Actinium Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 88,816 shares of ATNM stock, worth $109,243. This represents 0.0% of its overall portfolio holdings.

Number of Shares

88,816

Previous 36,979 140.18%

Holding current value

$109,243

Previous $69,000 60.87%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.12 - $1.93 $58,057 - $100,045	51,837 Added 140.18%	88,816 $111,000
Q3 2024 Nov 14, 2024	BUY	$1.72 - $8.0 $24,432 - $113,640	14,205 Added 62.37%	36,979 $69,000
Q2 2024 Aug 13, 2024	SELL	$6.56 - $9.89 $32,419 - $48,876	-4,942 Reduced 17.83%	22,774 $168,000
Q1 2024 May 13, 2024	SELL	$5.0 - $9.2 $10,205 - $18,777	-2,041 Reduced 6.86%	27,716 $217,000
Q4 2023 Feb 09, 2024	BUY	$4.02 - $6.08 $70,727 - $106,971	17,594 Added 144.65%	29,757 $151,000
Q3 2023 Nov 09, 2023	BUY	$5.91 - $7.37 $71,883 - $89,641	12,163 New	12,163 $72,000
Q1 2023 May 12, 2023	SELL	$8.51 - $14.26 $4,518 - $7,572	-531 Reduced 16.41%	2,704 $25,000
Q4 2022 Feb 08, 2023	BUY	$7.05 - $14.41 $9,862 - $20,159	1,399 Added 76.2%	3,235 $34,000
Q3 2022 Nov 10, 2022	BUY	$4.81 - $8.48 $8,658 - $15,264	1,800 Added 5000.0%	1,836 $13,000
Q2 2022 Aug 10, 2022	BUY	$4.71 - $7.11 $169 - $255	36 New	36 $0
Q1 2022 May 16, 2022	SELL	$4.57 - $6.4 $228 - $320	-50 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.01 - $8.8 $601 - $880	-100 Reduced 66.67%	50 $0
Q3 2021 Nov 15, 2021	SELL	$5.76 - $9.67 $15,511 - $26,041	-2,693 Reduced 94.72%	150 $1,000
Q2 2021 Aug 13, 2021	BUY	$7.01 - $8.63 $18,877 - $23,240	2,693 Added 1795.33%	2,843 $22,000
Q1 2021 May 12, 2021	BUY	$7.62 - $9.79 $1,143 - $1,468	150 New	150 $1,000

Others Institutions Holding ATNM

# of Institutions

Shares Held

7.94M

Call Options Held

59.6K

Put Options Held

4.8K

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $31M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account